Loading...

Momenta Pharmaceuticals

DB:LZ1
Snowflake Description

Excellent balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
LZ1
DB
$1B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. The last earnings update was 56 days ago. More info.


Add to Portfolio Compare Print
LZ1 Share Price and Events
7 Day Returns
-5.3%
DB:LZ1
-1.4%
DE Biotechs
2.4%
DE Market
1 Year Returns
-27.1%
DB:LZ1
-10.6%
DE Biotechs
-6.2%
DE Market
LZ1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Momenta Pharmaceuticals (LZ1) -5.3% -3.1% 18.4% -27.1% 37.4% 51.6%
DE Biotechs -1.4% 2.6% -7.7% -10.6% 54.2% 8%
DE Market 2.4% 3% 7.4% -6.2% 9.6% 14.1%
1 Year Return vs Industry and Market
  • LZ1 underperformed the Biotechs industry which returned -10.6% over the past year.
  • LZ1 underperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
LZ1
Industry
5yr Volatility vs Market
Related Companies

LZ1 Value

 Is Momenta Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Momenta Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €11.912.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Momenta Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Momenta Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:LZ1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.26
NasdaqGS:MNTA Share Price ** NasdaqGS (2019-04-18) in USD $13.89
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.41x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Momenta Pharmaceuticals.

DB:LZ1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:MNTA Share Price ÷ EPS (both in USD)

= 13.89 ÷ -2.26

-6.14x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Momenta Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Momenta Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Momenta Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:LZ1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.14x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
8.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Momenta Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Momenta Pharmaceuticals's assets?
Raw Data
DB:LZ1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $4.85
NasdaqGS:MNTA Share Price * NasdaqGS (2019-04-18) in USD $13.89
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.85x
DB:LZ1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:MNTA Share Price ÷ Book Value per Share (both in USD)

= 13.89 ÷ 4.85

2.86x

* Primary Listing of Momenta Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Momenta Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Momenta Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Momenta Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

LZ1 Future Performance

 How is Momenta Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
8.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Momenta Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare Momenta Pharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Momenta Pharmaceuticals's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Momenta Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:LZ1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:LZ1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 8.6%
DB:LZ1 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 7.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:LZ1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:LZ1 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 104 -115 -58 4
2022-12-31 63 -62 -156 4
2021-12-31 55 -102 -158 5
2020-12-31 50 -119 -157 5
2019-12-31 48 -123 -155 5
DB:LZ1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 76 -156 -176
2018-09-30 97 -161 -154
2018-06-30 107 -144 -137
2018-03-31 117 -132 -104
2017-12-31 139 -29 -88
2017-09-30 108 53 -60
2017-06-30 114 55 -45
2017-03-31 116 57 -29
2016-12-31 110 9 -21
2016-09-30 98 -60 -92
2016-06-30 82 -36 -104
2016-03-31 101 -29 -85

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Momenta Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Momenta Pharmaceuticals's revenue is expected to grow by 7.4% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:LZ1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Momenta Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:LZ1 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -1.02 -0.19 -1.73 4.00
2022-12-31 -1.63 -0.46 -2.72 5.00
2021-12-31 -1.56 -0.65 -2.33 6.00
2020-12-31 -1.61 -0.86 -2.16 6.00
2019-12-31 -1.73 -1.24 -2.10 6.00
DB:LZ1 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.26
2018-09-30 -2.03
2018-06-30 -1.82
2018-03-31 -1.39
2017-12-31 -1.20
2017-09-30 -0.84
2017-06-30 -0.64
2017-03-31 -0.42
2016-12-31 -0.31
2016-09-30 -1.34
2016-06-30 -1.53
2016-03-31 -1.28

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Momenta Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Momenta Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Momenta Pharmaceuticals has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

LZ1 Past Performance

  How has Momenta Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Momenta Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Momenta Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Momenta Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Momenta Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Momenta Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Momenta Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:LZ1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 75.59 -176.06 85.11 74.01
2018-09-30 97.38 -154.06 79.41 80.09
2018-06-30 106.58 -136.95 79.67 82.01
2018-03-31 117.12 -103.97 79.71 79.40
2017-12-31 138.88 -88.10 82.21 76.76
2017-09-30 108.47 -60.32 84.55 79.64
2017-06-30 113.52 -44.67 79.60 78.89
2017-03-31 116.38 -28.75 71.92 80.42
2016-12-31 109.62 -21.00 64.47 78.71
2016-09-30 97.82 -91.71 60.67 78.23
2016-06-30 82.47 -104.21 57.38 77.62
2016-03-31 100.94 -85.45 55.81 77.67
2015-12-31 89.65 -83.31 48.05 73.45
2015-09-30 88.44 -70.13 44.80 71.59
2015-06-30 83.98 -69.18 43.45 71.29
2015-03-31 50.03 -93.12 41.34 69.24
2014-12-31 52.25 -98.60 45.16 74.03
2014-09-30 43.82 -112.68 44.89 75.39
2014-06-30 45.24 -108.96 42.76 74.29
2014-03-31 38.65 -111.65 43.06 72.25
2013-12-31 35.47 -108.41 41.06 69.75
2013-09-30 35.44 -96.02 39.58 66.01
2013-06-30 29.79 -96.46 41.61 96.27
2013-03-31 47.30 -77.78 42.44 79.40
2012-12-31 63.92 -58.65 43.68 62.66
2012-09-30 80.65 -42.22 44.02 47.39
2012-06-30 163.49 43.94 44.51

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Momenta Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Momenta Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Momenta Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Momenta Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Momenta Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

LZ1 Health

 How is Momenta Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Momenta Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Momenta Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Momenta Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Momenta Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 422.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Momenta Pharmaceuticals Company Filings, last reported 3 months ago.

DB:LZ1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 461.01 1.04 422.41
2018-09-30 248.76 0.00 275.08
2018-06-30 281.69 0.00 310.83
2018-03-31 334.42 0.00 323.90
2017-12-31 374.15 0.00 342.67
2017-09-30 360.51 0.00 418.79
2017-06-30 386.86 0.00 446.55
2017-03-31 370.32 0.00 433.75
2016-12-31 371.91 0.00 353.15
2016-09-30 325.78 0.00 308.96
2016-06-30 334.64 0.00 336.92
2016-03-31 351.48 0.00 345.79
2015-12-31 369.98 0.00 350.04
2015-09-30 393.26 0.00 374.87
2015-06-30 416.64 0.00 377.17
2015-03-31 216.70 0.00 198.70
2014-12-31 206.37 0.00 191.53
2014-09-30 200.36 0.00 176.46
2014-06-30 225.37 0.00 202.28
2014-03-31 247.75 0.00 223.95
2013-12-31 269.84 0.00 245.68
2013-09-30 295.99 0.00 275.90
2013-06-30 314.92 0.00 300.16
2013-03-31 340.05 0.00 324.20
2012-12-31 360.49 0.00 340.60
2012-09-30 374.72 0.00 361.82
2012-06-30 396.31 0.00 372.31
  • Momenta Pharmaceuticals's level of debt (0.2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 0.2% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Momenta Pharmaceuticals has sufficient cash runway for 2.6 years based on current free cash flow.
  • Momenta Pharmaceuticals has sufficient cash runway for 2 years if free cash flow continues to grow at historical rates of 56.1% each year.
X
Financial health checks
We assess Momenta Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Momenta Pharmaceuticals has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

LZ1 Dividends

 What is Momenta Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Momenta Pharmaceuticals dividends.
If you bought €2,000 of Momenta Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Momenta Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Momenta Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:LZ1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:LZ1 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Momenta Pharmaceuticals has not reported any payouts.
  • Unable to verify if Momenta Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Momenta Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Momenta Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Momenta Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Momenta Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Momenta Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

LZ1 Management

 What is the CEO of Momenta Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Craig Wheeler
COMPENSATION $4,784,639
AGE 58
TENURE AS CEO 12.6 years
CEO Bio

Mr. Craig A. Wheeler has been the Chief Executive Officer and President of Momenta Pharmaceuticals Inc. since September 12, 2006 and August 22, 2006, respectively. Mr. Wheeler has been an Executive Director at Momenta Pharmaceuticals Inc. since August 22, 2006. He was Principal Financial Officer and Principal Accounting Officer of Momenta Pharmaceuticals since May 8, 2018 to October 5, 2018. He led Momenta through the launch of its first complex drug products, including the first generic versions of LOVENOX and once-daily COPAXONE. He has also overseen the growth into a diversified business, with a development pipeline of biosimilar biologics as well as novel therapeutics for oncology and autoimmune indications at Momenta Pharmaceuticals. He served as the Board Chairman, Treasurer and Secretary of Generic Pharmaceutical Association until February 22, 2016. Mr. Wheeler served as a Vice President of Chiron Corp. from August 2001 to June 2006. Prior to joining Momenta, he served as the President of Chiron Biopharmaceuticals, a division of Chiron Corp. from August 2001 to June 2006. He was responsible for all aspects of the Biopharmaceuticals business unit, including commercial, research, development and manufacturing. During his tenure at Chiron, he led the restructuring of the business unit to refocus on oncology and infectious disease. Mr. Wheeler served as a Partner and served as a Senior Member of health care practice at The Boston Consulting Group and a key contributor to its practice in hospital strategy, disease management and pharmaceutical capabilities from August 1988 to August 2001. He began his career at Merck & Company, Inc.'s MSDRL research unit. Mr. Wheeler served as a Senior Engineer in process development at Merck's MSDRL research unit. He served as the Leader of Scientist's Network at The Boston Consulting Group. In partnership with Rockefeller Foundation, he has joined Global Alliance for TB Drug Development. He served as a Financial Analyst for Hybritech. He has extensive professional experience in the biotechnology and healthcare industries. Mr. Wheeler served as the Chairman of Avanir Pharmaceuticals, Inc. from May 3, 2007 to January 13, 2015 and GPhA from 2014 to February 2016. He serves as a Director of Association for Accessible Medicines. He has been a Director of Amicus Therapeutics, Inc. since June 10, 2016. Mr. Wheeler has extensive pharmaceutical industry knowledge and leadership experience, including his demonstrated expertise in drug development, manufacturing and the technical issues facing growing biopharmaceutical companies. Mr. Wheeler serves as a Director of California Healthcare Institute. He serves as a Member of the Chief Executive Officer Roundtable on Cancer, Inc. He also serves on the IBM Life Science Strategic Advisory Council and the Whitehead Institute for Biomedical Research's Board of Associates. He served as a Director of Association for Accessible Medicines (a/k/a Generic Pharmaceutical Association) until February 22, 2016. Mr. Wheeler served as a Director of Avanir Pharmaceuticals, Inc. from September 27, 2005 to January 13, 2015. In 2011, Mr. Wheeler was an E&Y Entrepreneur of the Year Regional Award winner. Mr. Wheeler holds BS and an MS Degree in Chemical Engineering from Cornell University and an MBA from the Wharton School of the University of Pennsylvania, where he majored in Marketing and Finance.

CEO Compensation
  • Craig's compensation has increased whilst company is loss making.
  • Craig's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Momenta Pharmaceuticals management team in years:

0.5
Average Tenure
55.5
Average Age
  • The average tenure for the Momenta Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

Craig Wheeler

TITLE
President
COMPENSATION
$5M
AGE
58
TENURE
12.6 yrs

Ganesh Kaundinya

TITLE
Co-Founder & Consultant
COMPENSATION
$2M
AGE
51

Santiago Arroyo

TITLE
Chief Medical Officer & Senior VP of Development
COMPENSATION
$3M
TENURE
1.8 yrs

Bruce Leicher

TITLE
Consultant
COMPENSATION
$2M
AGE
62
TENURE
0.5 yrs

Scott Storer

TITLE
Consultant
COMPENSATION
$569K
TENURE
0.5 yrs

Michelle Robertson

TITLE
Principal Accounting Officer
AGE
50
TENURE
0.5 yrs

Tony Manning

TITLE
Chief Scientific Officer
AGE
56
TENURE
0.5 yrs

Patty Eisenhaur

TITLE
Vice President of Investor Relations & Communications
AGE
55
TENURE
0.3 yrs

Alejandra Carvajal

TITLE
Chief Legal Officer
TENURE
0.5 yrs

Young Kwon

TITLE
Chief Business Officer
Board of Directors Tenure

Average tenure and age of the Momenta Pharmaceuticals board of directors in years:

3.3
Average Tenure
63
Average Age
  • The tenure for the Momenta Pharmaceuticals board of directors is about average.
Board of Directors

Bruce Downey

TITLE
Chairman
COMPENSATION
$273K
AGE
71
TENURE
0.8 yrs

Craig Wheeler

TITLE
President
COMPENSATION
$5M
AGE
58
TENURE
12.7 yrs

Liz Stoner

TITLE
Director
COMPENSATION
$270K
AGE
68
TENURE
11.5 yrs

Georges Gemayel

TITLE
Director
COMPENSATION
$270K
AGE
58
TENURE
3.3 yrs

Corey Fishman

TITLE
Director
COMPENSATION
$268K
AGE
53
TENURE
2.6 yrs

Robert Pollock

TITLE
Member of Regulatory Advisory Board

Thomas Garvey

TITLE
Member of Regulatory Advisory Board

J. Crout

TITLE
Member of Regulatory Advisory Board
AGE
88

Benito Casu

TITLE
Member of Scientific Advisory Board

Richard Cooper

TITLE
Member of Regulatory Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Momenta Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Momenta Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

LZ1 News

Simply Wall St News

LZ1 Company Info

Description

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The company’s biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.

Details
Name: Momenta Pharmaceuticals, Inc.
LZ1
Exchange: DB
Founded: 2001
$1,213,867,452
98,281,000
Website: http://www.momentapharma.com
Address: Momenta Pharmaceuticals, Inc.
301 Binney Street,
Cambridge,
Massachusetts, 02142,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS MNTA Common Stock Nasdaq Global Select US USD 22. Jun 2004
DB LZ1 Common Stock Deutsche Boerse AG DE EUR 22. Jun 2004
Number of employees
Current staff
Staff numbers
131
Momenta Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 20:33
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/04
Last earnings filing: 2019/02/22
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.